Why DermTech Stock Gained 26% Last Month

What happenedShares of DermTech (NASDAQ: DMTK), a biotech company focused on skin-cancer testing, gained last month as the company continued to attract positive analyst attention and build on momentum from last December. Back then, the company announced results from a TRUST studyRead MoreMarketsMarkets Feed